Novartis Transderm Scop Superiority Claim Disputed In Pharmacia Petition
This article was originally published in The Tan Sheet
Pharmacia is asking FDA to modify the physician package insert for Novartis' Transderm Scop Rx motion sickness patch to remove a statement claiming superiority to OTC oral dimenhydrinate.
You may also be interested in...
DTC ad claims for Novartis' Rx Transderm Scop declaring superiority to Pharmacia's OTC motion sickness remedy Dramamine are inappropriate due to "very significant differences" between the scopolamine patch's consumer-targeted claims and original FDA-reviewed statements, NAD states Nov. 8.
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning